Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Anti-tumor therapy strategy of CAR-T cells based on stem cell memory and central memory cells].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
December 2024
Center for Cancer Immunotherapy, Institute of Biomedicine and Biotechnology, Chinese Academy of Sciences, Shenzhen 518055; University of Chinese Academy of Sciences, Beijing 101408; Laboratory of Human Environmental Epigenomes, Department of Biopharmaceutical Sciences, School of Pharmaceutical Science, Shenzhen University of Advanced Technology, Shenzhen 518107, China.*Corresponding author, E-mail:
Cancer immunotherapy including immune checkpoint inhibitors and adoptive cell therapy has gained revolutionary success in the treatment of hematologic tumors; however, it only gains limited success in solid tumors. For example, chimeric antigen receptor T (CAR-T) cell therapy has shown significant effects and potential for curing patients with B-cell malignancies. In contrast, it remains a challenge for CAR-T cell therapy to gain similar success in solid tumors.
View Article and Find Full Text PDFCAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives.
Front Immunol
January 2025
Innovation & Research Department, OriCell Therapeutics Co. Ltd., Shanghai, China.
Systemic lupus erythematosus (SLE) and lupus nephritis (LN) are debilitating autoimmune disorders characterized by pathological autoantibodies production and immune dysfunction, causing chronic inflammation and multi-organ damage. Despite current treatments with antimalarial drugs, glucocorticoids, immunosuppressants, and monoclonal antibodies, a definitive cure remains elusive, highlighting an urgent need for novel therapeutic strategies. Recent studies indicate that chimeric antigen receptor T-cell (CAR-T) therapy has shown promising results in treating B-cell malignancies and may offer a significant breakthrough for non-malignant conditions like SLE.
View Article and Find Full Text PDF[Reactivation of cytomegalovirus and its influencing factors in patients with B-lymphocyte malignancy after CAR-T cell therapy].
Zhonghua Xue Ye Xue Za Zhi
November 2024
The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou 215006, China.
This study aimed to analyze cytomegalovirus (CMV) reactivation and its influencing factors in patients with B-lymphocyte malignancy who received chimeric antigen receptor T (CAR-T) cell therapy. This study retrospectively reviewed patients with B-lymphocyte malignancy who received CAR-T cell therapy in the First Affiliated Hospital of Soochow University from January 2021 to December 2023. The data of patients who underwent CMV-DNA detection and/or pathogen metagenomic sequencing twice or more within 100 days after CAR-T cell therapy were analyzed.
View Article and Find Full Text PDF[Clinical Features and Prognosis of Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
Objective: To investigate the clinical features, gene mutation profile, efficacy and prognostic factors of primary extranodal diffuse large B-cell lymphoma(EN-DLBCL).
Methods: A retrospective analysis was performed for 382 patients with primary EN-DLBCL with complete clinical data who were treated in West China Hospital from January 2013 to January 2023, and their clinical characteristics,gene mutation profile, efficacy and prognostic factors were analyzed.
Results: The median age of the 382 patients with EN-DLBCL was 56(18-89) years old.
A comprehensive immune repertoire signature distinguishes pulmonary infiltration in SARS-CoV-2 Omicron variant infection.
Front Immunol
January 2025
Shanghai Cancer Institute, Shanghai, China.
Introduction: The coronavirus disease 2019 (COVID-19) global pandemic has been the most severe public health emergency since 2019. Currently, the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been the most dominant. The most prominent symptom of SARS-CoV-2 infection is respiratory.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!